<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284308</url>
  </required_header>
  <id_info>
    <org_study_id>ELDAPT</org_study_id>
    <nct_id>NCT02284308</nct_id>
  </id_info>
  <brief_title>Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy</brief_title>
  <acronym>ELDAPT</acronym>
  <official_title>ELDAPT: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the oPtimal Treatment Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no detailed information available on benefits and harms of intensified treatment
      with concurrent RCHT among a subpopulation of elderly patients. Reliable tools are needed to
      distinguish the subgroup of fit patients from frail patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is a problem of the elderly: 30% of the lung cancer patients are aged ≥ 75 years.
      Due to underrepresentation of elderly patients in clinical trials there is a lack of evidence
      to select the optimal treatment strategy for these patients. Concurrent radiochemotherapy
      (RCHT) has been recognised as the standard treatment of stage III NSCLC patients with a good
      performance status. Evidence for this treatment was gained in clinical trials that mostly
      excluded elderly patients. Furthermore, the survival gain obtained with combined RCHT, comes
      with a significant increase in toxicity. Therefore, information on benefits and harms of
      intensified treatment with concurrent RCHT among a subpopulation of medically fit elderly
      patients is still lacking. Moreover, reliable tools are needed to distinguish the subgroup of
      fit patients from frail patients, i.e. those expected to experience important toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QAS (quality adjusted survival)</measure>
    <time_frame>yearly until death (average 10 years)</time_frame>
    <description>To compare concurrent and sequential RCHT with respect to quality-adjusted survival (QAS) in elderly patients (≥75 years) with stage III NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>To perform geriatric assessment in stage III NSCLC patients to select patients fit enough to undergo intensified treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliable predictive elements</measure>
    <time_frame>5 years</time_frame>
    <description>To identify reliable elements of the geriatric assessment that are predictive for treatment tolerance and QAS in elderly patients with stage III NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the predictive value of blood biomarkers, cardiac ejection fraction and physical performance measures with respect to treatment tolerance and QAS in elderly patients with stage III NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development and validation of geriatric screening instrument</measure>
    <time_frame>5 years</time_frame>
    <description>To develop and validate a clinically applicable geriatric screening instrument that enables appropriate treatment stratification in the elderly NSCLC patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical comparison between treatments</measure>
    <time_frame>5 years</time_frame>
    <description>To compare concurrent and sequential RCHT in fit elderly patients with respect to overall and progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>End of study</time_frame>
    <description>To compare cost-effectiveness of sequential and concurrent RCHT for fit elderly patients with stage III NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical comparison between treatments with respect to preservation of functional capacity/independence</measure>
    <time_frame>5 years</time_frame>
    <description>To compare concurrent and sequential RCHT in fit elderly patients with respect to preservation of functional capacity/independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical comparison between treatments with respect to overall and lung-cancer specific QOL</measure>
    <time_frame>5 years</time_frame>
    <description>Tom compare concurrent and sequential RCHT in fit elderly patients with respect to overall and lung-cancer specific Qol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Concurrent RCHT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoposide (day 1, 2 and 3) and cisplatin (day 1) every 3 weeks, 3 cycles)
Etoposide (day 1, 2 and 3) and carboplatin (every 3 weeks, 3 cycles)
Cisplatin (daily)
Pemetrexed/Alimta and cisplatin (day 1 every 3 weeks, 3 cycles)
Pemetrexed/Alimta and carboplatin (day 1 every 3 weeks, 3 cycles)
Radiation schedule:
Radiotherapy in both arms is delivered to a minimal total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the mininimal TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential RCHT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed/Alimta and cisplatin day 1 every 3 weeks, 3 cycles,
Pemetrexed/Alimta and carboplatin (every 3 weeks, 3 cycles),
Gemcitabine (day 1 and 8) and cisplatin (day 1) every 3 weeks, 3 cycles)
Gemcitabine (day 1 and 8) and carboplatin, (day 1 every 3 weeks, 3 cycles)
Radtiation schedule:
Radiotherapy in both treatment arms is delivered to a minimum total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the minimum TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>An extra withdrawal of blood, during a routine blood withdrawal. This is an optional inverventions for patients.</description>
    <arm_group_label>Concurrent RCHT</arm_group_label>
    <arm_group_label>Sequential RCHT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any subtype of NSCLC, primary UICC stage III

          -  Age ≥ 75 years

        Exclusion Criteria:

          -  Not any subtype of NSCLC, primary UICC stage III

          -  Younger than 75 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith van Loon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAASTRO clinic (radiotherapist)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Marie Dingemans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>azM/MUMC (pulmonologist)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariska Janssen-Heijnen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VieCuri Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith van Loon, MD, PhD</last_name>
    <phone>+31 88 44 55 666</phone>
    <email>judith.vanloon@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadja Drummen</last_name>
    <phone>+31 88 44 55 817</phone>
    <email>nadja.drummen@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veerle Surmont</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherepiegroep</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcel Stam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caniusius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yvonne Berk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <state>Overijssel</state>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeske Staal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suzy Samii</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ernest Vonk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N Pronk, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>N Pronk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Claessens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joachim Aerts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Centre Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaar Maas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben van den Borne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuyderland</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerben Bootsma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajen Ramai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith van Loon, MD, PhD</last_name>
      <phone>+31 88 44 55 666</phone>
      <email>judith.vanloon@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nadja Drummen</last_name>
      <phone>+31 88 44 55 817</phone>
      <email>nadja.drummen@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Judith van Loon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Dingemans, MD, PhD</last_name>
      <phone>+31 43 387 65 43</phone>
      <email>a.dingemans@maastro.nl</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Dingemans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olga Schuurbiers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laurentius Hospital</name>
      <address>
        <city>Roermond</city>
        <zip>6043 VC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cordula Pitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medical Centre</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Westenend</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

